SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

Octavio A. Romero(Josep Carreras Leukaemia Research Institute), Montse Sánchez‐Céspedes(Josep Carreras Leukaemia Research Institute)
Nature Communications
July 14, 2021
Cited by 59


Related Papers